Authors
Latest:
Expert explains challenges of telehealthAlthough much of the discourse around telehealth rightfully focuses on its benefits, the potential drawbacks and limitations are often glossed over, particularly around provider burden.
Latest:
Low-Grade, Intermediate-Risk NMIBC: The Hidden LesionPanelists discuss how UGN-102, a reverse thermal hydrogel formulation of mitomycin, offers an FDA-approved ablative treatment option for patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC), demonstrating 80% complete response rates in the ENVISION trial (NCT05243550) and allowing for the de-escalation of surveillance and reduced surgical burden.
Latest:
Ensuring operational continuity is critical with healthcare data breachesWith healthcare data breaches approaching a boiling point, care providers need to adopt an approach that prioritizes operational continuity.
Latest:
Anktiva as a lymphocyte rescue molecule: Unlocking the power of NK cells and T cells"One way to think about how Anktiva works is it is the first molecule, based on the package insert, that increases and proliferates the NK cells, the T cells, and the CD4+ and CD8+ T cells, without up-regulating the suppressive T cells," says Patrick Soon-Shiong, MD.
Latest:
Raveen Syan, MD, shares 2025 Urology on the Beach highlights"I know this year we're going to see even more companies producing more products, more results, and hopefully really help change and improve patient outcomes, especially when it comes to overactive bladder," says Raveen Syan, MD, FPMRS.
Latest:
Frontline Therapy for Non-Metastatic Muscle-Invasive Bladder CancerFrontline treatment approaches recommended by urologists and medical oncologists for patients with non-metastatic muscle-invasive bladder cancer.
Latest:
Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma"At ASCO GU, we presented the final analysis of the study, which confirmed the superiority of a combination over the TKI monotherapy in terms of both progression-free survival as well as overall survival," says Camillo Porta, MD.
Latest:
Managing aging and frailty in the urologic cancer populationIncreasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.
Latest:
Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera’s SNM deviceBeyond clinical metrics, Pezzella praised the device’s user-friendly, sophisticated design.
Latest:
Ronney Abaza, MD, FACS, on what’s coming down the pike in robotic surgery“We're really excited as robotic surgeons, because this will be the first time in a couple decades that there'll be competition for robots, and that's only going to make things better,” says Ronney Abaza, MD, FACS.
Latest:
Cretostimogene grenadenorepvec made available through expanded access programCretostimogene grenadenorepvec is an intravesical oncolytic immunotherapy currently under investigation in phase 3 trials.
Latest:
Pearls & Perspectives: Updates in testosterone therapy, with Andrew Sun, MD at AUA 2025Andrew Sun, MD, joins Pearls & Perspectives to discuss innovative approaches to testosterone therapy for enhanced health outcomes.
Latest:
Investigational HIF-2α inhibitor shows activity, safety in advanced clear cell RCCThis monotherapy was safe for all doses and dosing schedules observed in the study and daily doses showed initial antitumor activity.
Latest:
Update on advanced imaging in prostate cancerAdvances allow for more accurate detection of metastatic disease.
Latest:
Martin Sanda, MD, considers potential future advancements in urologyAccording to Sanda, future advancements may involve gene and RNA sequencing, the use of AI in imaging, and multidisciplinary collaboration.
Latest:
The emotional toll of surgical complications on urologic surgeons"It is important as a field that we recognize the potential emotional impact of surgical adverse events," writes Amy N. Luckenbaugh, MD.
Latest:
We got a little MIST-y at this year’s AUA Annual MeetingUrologist Garrett D. Pohlman, MD, reflects on the benign prostatic hyperplasia offerings from the 2025 American Urological Association Annual Meeting.
Latest:
Lymph nodes in bladder cancer: Past, present, and future"Based on the LEA and S1011 trials, it has become clear that patients do not benefit from an extended LND, and a standard bilateral pelvic LND is the standard of care," write Amir Soltani-Tehrani, MD, and Kamal S. Pohar, MD.
Latest:
Ongoing Studies Investigating Rectal Spacer Benefits in Patients With Prostate Cancer Undergoing Radiation TherapyDr Daniel Allan Hamstra highlights ongoing and planned trials investigating rectal spacers in patients with prostate cancer undergoing radiation therapy that he hopes will provide more data on toxicity reduction and preservation of sexual function.
Latest:
Trends in urology: Arpeet Shah, MD, on challenges and opportunities in 2025Arpeet Shah, MD, highlights the shift toward precision medicine, ongoing work force challenges, the integration of AI, and more.
Latest:
Joseph Jacob, MD, on the durability of TAR-200 in NMIBCJoseph Jacob, MD, outlines key findings on TAR-200 monotherapy from cohort 2 of the SunRISe-1 study.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Brendan Browne, MD, on patient selection for HoLEP for BPH“The patients I find that have the most pronounced benefit are the patients with the very large prostates, or the patients who are catheter dependent with concern for neurogenic or myogenic bladder failure,” says Brendan M. Browne, MD.
Latest:
How to implement an ERAS pathway in your urology practiceProgram encompasses patient counseling, anesthetic planning, and early mobilization.
Latest:
AACU 2024 Advocacy Summit & Annual MeetingThis year, the AACU 2024 Advocacy Summit & Annual Meeting will focus on the intersection of health policy and clinical practice, as well as the impact of current state and national legislative trends on urology.
Latest:
Urology CNP discusses sensitivity in communication, physical exam“Oftentimes, [during] the very first visit, we are talking a lot. I am learning what's going on with them," says Anna Myers, CNP.
